- Published: January 10, 2022
- Updated: January 10, 2022
- University / College: King's College London
- Language: English
- Downloads: 10
A Corrigendum on
Transcriptome Analysis Showed a Differential Signature Between Invasive and Non-invasive Corticotrophinomas
by de Araújo, L. J. T., Lerario, A. M., de Castro, M., Martins, C. S., Bronstein, M. D., Machado, M. C., et al. (2017). Front. Endocrinol. 8: 55. doi: 10. 3389/fendo. 2017. 00055
In the original article, there was an error. We stated that USP8 genetic abnormalities were not identified in DNA from tumor samples analyzed by microarray technology.
A correction has been made toAbstract, Paragraph Number 1, Lines 18–19.
Somatic mutations in USP8 were also investigated and mutations were identified in six cases.
A correction has been made toResults, Paragraph Number 1.
Before microarray analysis, we performed the screening for mutations in USP8 in our patients, and somatic variants were found in patients #2 and #5 (p. Ser718Pro), #4 (p. Ser718Cys), patients #3 and #6 (p. Pro720Arg), and #9 (p. Pro720Gln). Both mutations were found in heterozygosis and have been previously described (17, 18).
A correction has been made toDiscussion, Paragraph Number 1.
In the microarray study cohort, we identified six USP8 mutations in 12 samples (50%). In the patients included in the validation study, we could identify somatic USP8 mutations in 5 (non-invasive corticotrophinomas) out of 18 patients (27. 7%). According to Reincke et al. (17) and Perez-Rivas et al. (18), these mutations occur in ≈36% of patients with CD. Interestingly, the presence of USP8 mutations did not interfere in the transcriptome expression analysis results comparing invasive vs. non-invasive tumors and in its validation study.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
